Identifying critically important vascular access outcomes for trials in haemodialysis: an international survey with patients, caregivers and health professionals.


Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
01 04 2020
Historique:
received: 01 02 2019
accepted: 18 06 2019
pubmed: 2 8 2019
medline: 27 10 2020
entrez: 2 8 2019
Statut: ppublish

Résumé

Vascular access outcomes reported across haemodialysis (HD) trials are numerous, heterogeneous and not always relevant to patients and clinicians. This study aimed to identify critically important vascular access outcomes. Outcomes derived from a systematic review, multi-disciplinary expert panel and patient input were included in a multilanguage online survey. Participants rated the absolute importance of outcomes using a 9-point Likert scale (7-9 being critically important). The relative importance was determined by a best-worst scale using multinomial logistic regression. Open text responses were analysed thematically. The survey was completed by 873 participants [224 (26%) patients/caregivers and 649 (74%) health professionals] from 58 countries. Vascular access function was considered the most important outcome (mean score 7.8 for patients and caregivers/8.5 for health professionals, with 85%/95% rating it critically important, and top ranked on best-worst scale), followed by infection (mean 7.4/8.2, 79%/92% rating it critically important, second rank on best-worst scale). Health professionals rated all outcomes of equal or higher importance than patients/caregivers, except for aneurysms. We identified six themes: necessity for HD, applicability across vascular access types, frequency and severity of debilitation, minimizing the risk of hospitalization and death, optimizing technical competence and adherence to best practice and direct impact on appearance and lifestyle. Vascular access function was the most critically important outcome among patients/caregivers and health professionals. Consistent reporting of this outcome across trials in HD will strengthen their value in supporting vascular access practice and shared decision making in patients requiring HD.

Sections du résumé

BACKGROUND
Vascular access outcomes reported across haemodialysis (HD) trials are numerous, heterogeneous and not always relevant to patients and clinicians. This study aimed to identify critically important vascular access outcomes.
METHOD
Outcomes derived from a systematic review, multi-disciplinary expert panel and patient input were included in a multilanguage online survey. Participants rated the absolute importance of outcomes using a 9-point Likert scale (7-9 being critically important). The relative importance was determined by a best-worst scale using multinomial logistic regression. Open text responses were analysed thematically.
RESULTS
The survey was completed by 873 participants [224 (26%) patients/caregivers and 649 (74%) health professionals] from 58 countries. Vascular access function was considered the most important outcome (mean score 7.8 for patients and caregivers/8.5 for health professionals, with 85%/95% rating it critically important, and top ranked on best-worst scale), followed by infection (mean 7.4/8.2, 79%/92% rating it critically important, second rank on best-worst scale). Health professionals rated all outcomes of equal or higher importance than patients/caregivers, except for aneurysms. We identified six themes: necessity for HD, applicability across vascular access types, frequency and severity of debilitation, minimizing the risk of hospitalization and death, optimizing technical competence and adherence to best practice and direct impact on appearance and lifestyle.
CONCLUSIONS
Vascular access function was the most critically important outcome among patients/caregivers and health professionals. Consistent reporting of this outcome across trials in HD will strengthen their value in supporting vascular access practice and shared decision making in patients requiring HD.

Identifiants

pubmed: 31369099
pii: 5542605
doi: 10.1093/ndt/gfz148
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

657-668

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Auteurs

Andrea K Viecelli (AK)

Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Australasian Kidney Trials Network, Centre for Health Services Research, University of Queensland, Brisbane, QLD, Australia.

Martin Howell (M)

Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia.
Centre for Kidney Research, Children's Hospital at Westmead, Sydney, NSW, Australia.

Allison Tong (A)

Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia.
Centre for Kidney Research, Children's Hospital at Westmead, Sydney, NSW, Australia.

Armando Teixeira-Pinto (A)

Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia.

Emma O'Lone (E)

Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia.
Centre for Kidney Research, Children's Hospital at Westmead, Sydney, NSW, Australia.

Angela Ju (A)

Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia.
Centre for Kidney Research, Children's Hospital at Westmead, Sydney, NSW, Australia.

Jonathan C Craig (JC)

College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.

Lai-Seong Hooi (LS)

Department of Medicine and Haemodialysis Unit, Hospital Sultanah Aminah, Johor Bahru, Malaysia.

Timmy Lee (T)

Department of Medicine and Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL, USA.
Section of Nephrology, Veterans Affairs Medical Center, Birmingham, AL, USA.

Charmaine E Lok (CE)

Division of Nephrology, University Health Network, Toronto, ON, Canada.
Department of Medicine, University of Toronto, Toronto, ON, Canada.

Kevan R Polkinghorne (KR)

Department of Nephrology, Monash Medical Centre, Melbourne, VC, Australia.
Department of Medicine, Monash University, Melbourne, VC, Australia.
School of Public Health and Preventive Medicine, Monash University, Melbourne, VC, Australia.

Robert R Quinn (RR)

Departments of Medicine & Community Health Sciences, University of Calgary, Calgary, AB, Canada.

Tushar J Vachharajani (TJ)

Department of Nephrology & Hypertension, Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.

Raymond Vanholder (R)

Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Department of Nephrology, Ghent University Hospital, Ghent, Belgium.

Li Zuo (L)

Department of Nephrology, Peking University People's Hospital, Beijing, China.

Jan Tordoir (J)

Department of Surgery, University Hospital Maastricht, Maastricht, The Netherlands.

Roberto Pecoits-Filho (R)

School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil.

Theodore Yuo (T)

Department of Surgery, Division of Vascular Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Pascal Kopperschmidt (P)

Fresenius Medical Care, Global Research & Development, Schweinfurt, Germany.

Rob Smith (R)

Nightcliff Renal Unit, Darwin, NT, Australia.

Ashley B Irish (AB)

Department of Nephrology, Fiona Stanley Hospital, Perth, WA, Australia.
Medical School, University of Western Australia, Perth, WA, Australia.

Trevor A Mori (TA)

Medical School, University of Western Australia, Perth, WA, Australia.

Elaine M Pascoe (EM)

Australasian Kidney Trials Network, Centre for Health Services Research, University of Queensland, Brisbane, QLD, Australia.

David W Johnson (DW)

Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Australasian Kidney Trials Network, Centre for Health Services Research, University of Queensland, Brisbane, QLD, Australia.
Translational Research Institute, Brisbane, QLD, Australia.

Carmel M Hawley (CM)

Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Australasian Kidney Trials Network, Centre for Health Services Research, University of Queensland, Brisbane, QLD, Australia.
Translational Research Institute, Brisbane, QLD, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH